Electronically Augmented Timed-Up-and-Go Test (EATUG) Differentiates Sit-To-Stand (STS) Mobility and Balance in Ambulatory Individuals with Amyotrophic Lateral Sclerosis (ambALS) and Parkinson Disease (ambPD) (P3.290)

Objective: To test the feasibility of using a body-fixed Inertial Measurement Unit (IMU), an electronic device that measures velocity, acceleration, and change in position, to provide insight into TUG performance in ambALS patients. Background: TUG evaluate mobility, balance, and risk of fall. It record the time required for a participant to stand up from a chair (STS), walk with 180 degree turn (WT), turn before sitting (TS), and sit down (SD). Patients with balance and mobility problems have longer TUG times. How each of the TUG segments relate to the impairment of balance and mobility in ambALS is not known. Methods: Maximum torso flexion/extension angle in degree (MTFEA), Peak Flexion/Peak Extension Angular Velocity (PFAV/PEAV in degrees per second), Peak Vertical Acceleration (PVA in meters per second2), Mean and peak turning angular velocity (MTAV/PTAV) were evaluated in 20 ambALS and 18 ambulatory individuals with Parkinson disease (ambPD) in 2 consecutive TUG tests wearing a chest-mounted IMU. Average of 2 consecutive trials was used for analysis. Independent t-tests were used to compare the performance of ALS vs. PD in the parameters of each TUG segment. Pearson correlation coefficient was used to determine the relationship between EATUG and patient clinical measures. Results: EATUG correlated with ALSFRSR-gross motor score (r=-0.584, p=0.007) and the UPDRS III score (r=0.773, p=0.001). No difference in total EATUG time (11±4 and 10±2) which slower than normal, or the percent of total EATUG time taken to perform each TUG segment between ALS and PD. In the STS segment, ambALS had statistically significant differences in MTFEA (p<.005) and PEAV (p<.001). Conclusions: EATUG significantly differentiates early abnormality during STS segment in ambALS compared with the AmbPD. AmbALS increase torso MTFEA, PFAV, and PEAV during STS, possibly to compensate for lower extremity weakness. Study Supported by: Carolinas ALS Research Fund, Carolinas HealthCare Foundation Disclosure: Dr. Sanjak has nothing to disclose. Dr. Hirsch has nothing to disclose. Dr. Habet has nothing to disclose. Dr. Peindl has nothing to disclose. Dr. Zheng has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Morgan has nothing to disclose. Dr. Mash has nothing to disclose. Dr. Englert has nothing to disclose. Dr. Iyer has nothing to disclose. Dr. Lucas has nothing to disclose. Dr. Russo has received personal compensation for activities with Teva Neuroscience and Biogen Idec as a consultant. Dr. Bravver has nothing to disclose. Dr. Bockenek has nothing to disclose. Dr. Brooks has nothing to disclose.